Ecuador Will Treat Foot Ulcers in Diabetic Patients with Cuba’s Heberprot-P

Recently, the Ecuadorian Health Ministry and the Cuban Heber Biotech Company agreed in Quito on the sale of some 9 000 doses of a new Cuban medication called Heberprot-P. The agreement was signed by Jorge Rodriguez, Cuba´s Ambassador to that South American nation, and Jose Maria Borja, Under Secretary of the local Foreign Ministry for Latin America and the Caribbean.

The first 500 Ecuadoran diabetic patients with foot ulcers are scheduled to be treated with this new Cuban medication, the only one of its type in the world capable of curing the ailment that otherwise could imply amputation.

Prensa Latina News Agency reported that the Cuban medical product is now being applied in Ecuador after the conclusion of the trial stage which was carried out with doses donated by Cuba.

90 percent effectiveness

During the signing ceremony, Jorge Mayo, representative of Biotech characterized the product as the son of Cuban science which, he said, has saved thousands of diabetic patients in the world from amputations.  He noted that there was a 90 percent effectiveness in the use of Heberprot – P, and that it has already been presented in several countries for its registry and has been patented in 14 nations of the European Union, Asia and Latin America, in addition to the US.

Francisco Vallejo, Under Secretary of Ecuador´s Health Ministry highlighted the importance of broadening its bilateral ties with Cuba and the nations of the Bolivarian Alliance for the Peoples of Our America (ALBA).  Vallejo expressed the view that the signing of this agreement was only one example of what can be achieved in favor of the health of the Ecuadoran people.

The Cuban Heber Biotech company has, in addition to Heberprot-P, other leading products like Interferon and the Pentavalente vaccine that immunizes infants against five diseases with only one dose

June 22 2012
Cuban News Agency

YESCuba News
Kingston, Jamaica